UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 159

Sortiert nach

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

Gynecologic oncology, 2020-11, Vol.159 (2), p.442-448

2020

Volltextzugriff (PDF)

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Annals of oncology, 2024-08, Vol.35 (8), p.728-738

2024

Volltextzugriff (PDF)

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

The New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158

2023

Volltextzugriff (PDF)

Improved activation of lumbar multifidus following spinal manipulation: a case report applying rehabilitative ultrasound imaging

The journal of orthopaedic and sports physical therapy, 2007-10, Vol.37 (10), p.613-619

2007

Volltextzugriff (PDF)

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

The New England journal of medicine, 2023-12, Vol.389 (23), p.2162-2174

2023

Volltextzugriff (PDF)

Scaphoid fracture in a patient after a fall

The journal of orthopaedic and sports physical therapy, 2012-06, Vol.42 (6), p.568-568

Buscema, Christopher J

2012

Volltextzugriff (PDF)

Total Cost of Cancer Care: Evaluating Health System Expenditures through Eight Performance Periods of the Oncology Care Model

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.S101

2022

Volltextzugriff (PDF)

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

The Lancet (British edition), 2010-09, Vol.376 (9744), p.875-885

2010

Volltextzugriff (PDF)

740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Annals of oncology, 2023-10, Vol.34, p.S507-S507

2023

Volltextzugriff (PDF)

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2008-09, Vol.372 (9641), p.807-816

2008

Volltextzugriff (PDF)

527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

Annals of oncology, 2022-09, Vol.33, p.S786-S787

2022

Volltextzugriff (PDF)

178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study

Annals of oncology, 2022-11, Vol.33, p.S1505-S1506

2022

Volltextzugriff (PDF)

LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004

Annals of oncology, 2021-09, Vol.32, p.S1309-S1309

2021

Volltextzugriff (PDF)

836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

Annals of oncology, 2020-09, Vol.31, p.S627-S628

2020

Volltextzugriff (PDF)

49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO

ESMO open, 2024-06, Vol.9, p.103556, Article 103556

2024

Volltextzugriff (PDF)

38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial

ESMO open, 2024-06, Vol.9, p.103538, Article 103538

2024

Volltextzugriff (PDF)

Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial

Annals of oncology, 2017-09, Vol.28, p.v330-v330

2017

Volltextzugriff (PDF)

Data Mining Applications Using Artificial Adaptive Systems

1. Aufl., 2013

Volltextzugriff (PDF)

Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial

International journal of gynecological cancer, 2019-11, Vol.29 (Suppl 4), p.A15-A16

2019

Volltextzugriff (PDF)

The effect of the substrate on the Raman and photoluminescence emission of single-layer MoS2

Nano research, 2014-04, Vol.7 (4), p.561-571

2014

Volltextzugriff (PDF)

Placental site trophoblastic tumor in a postmenopausal woman

American journal of clinical pathology, 1991-05, Vol.95 (5), p.670-674

1991

Volltextzugriff (PDF)

The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population

Cardiology, 2008-01, Vol.110 (4), p.271-282

2008

Volltextzugriff (PDF)

A Case Report of Recurrent Epithelial Ovarian Cancer Metastatic to the Sternum, Diaphragm, Costae, and Bowel Managed by Aggressive Secondary Cytoreductive Surgery without Postoperative Chemotherapy

Gynecologic oncology, 2002-07, Vol.86 (1), p.91-94

2002

Volltextzugriff (PDF)

Genital Warts, Papillomaviruses, and Genital Malignancies

Annual review of medicine, 1988, Vol.39 (1), p.371-379

1988

Volltextzugriff (PDF)

Characterization of Human Papillomavirus Type 45, a New Type 18-related Virus of the Genital Tract

Journal of general virology, 1987-12, Vol.68 (12), p.3073-3079

1987

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(147)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(46)
Humans
(45)
Female
(40)
Technology
(24)
Adult
(23)
Biological And Medical Sciences
(21)
Physical Sciences
(21)
Oncology
(20)
Medical Sciences
(19)
Middle Aged
(19)
Obstetrics & Gynecology
(19)
Materials Science
(18)
Aged
(17)
Materials Science, Multidisciplinary
(17)
Physics
(16)
Gynecology. Andrology. Obstetrics
(14)
Physics, Applied
(14)
Tumors
(14)
Female Genital Diseases
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Improved activation of lumbar multifidus following spinal manipulation: a case report applying rehabilitative ultrasound imaging

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Scaphoid fracture in a patient after a fall

Total Cost of Cancer Care: Evaluating Health System Expenditures through Eight Performance Periods of the Oncology Care Model

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study

178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study

LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004

836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO

38MO Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial

Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial

Data Mining Applications Using Artificial Adaptive Systems

Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial

The effect of the substrate on the Raman and photoluminescence emission of single-layer MoS2

Placental site trophoblastic tumor in a postmenopausal woman

The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population

A Case Report of Recurrent Epithelial Ovarian Cancer Metastatic to the Sternum, Diaphragm, Costae, and Bowel Managed by Aggressive Secondary Cytoreductive Surgery without Postoperative Chemotherapy

Genital Warts, Papillomaviruses, and Genital Malignancies

Characterization of Human Papillomavirus Type 45, a New Type 18-related Virus of the Genital Tract

Suchergebnisse filtern